



the**Hydroponics**company

www.thcl.com.au

ASX RELEASE (13th July, 2017)

MEDICINAL CANNABIS LICENCES – UPDATE

The Hydroponics Company (ASX:THC) (THC or Company) advises in response to shareholder enquiries the following:

The Hydroponics Company Limited, through its 100% owned medicinal cannabis subsidiary, Candeo Limited (**Candeo**), is building a domestic medicinal cannabis production and supply capability. This is being achieved through the licensing program established under the Narcotic Drugs Act 1967.

There are three relevant licences issued by the Office of Drug Control:

- A cannabis research licence allows the production of cannabis strains for research into medicinal use;
- a medicinal cannabis licence allows either cultivation or production or both of medicinal cannabis plants; and
- a manufacturing licence allows the manufacture of cannabis and cannabis extract into medicinal cannabis.

Candeo received a cannabis research licence on 6 July 2017. Candeo's application for a medicinal cannabis licence is progressing in its assessment and a manufacturing licence application is currently under development.

THC will advise the market when the licences are granted and also with regard its domestic medicinal cannabis production and supply capability.

For further information, please contact:

Henry Kinstlinger,
Company Secretary

P: +61 2 9251 7177



The Hydroponics Company Limited
(ASX:THC) ACN: 614 508 039

Level 2, 131 Macquarie Street,
Sydney, NSW, Australia. 2000.